López-Guerrero Jose A, Casanova-Salas Irene, Fernández-Serra Antonio, Rubio Luis, Calatrava Ana, García-Flores María, García-Casado Zaida, Rubio-Briones José
Laboratorio de Biología Molecular. Fundación Instituto Valenciano de Oncología. Valencia. España.
Arch Esp Urol. 2014 Jun;67(5):462-72.
Identification of biomarkers that, at the time of diagnosis of prostate cancer (PCa), are associated with presence of disease or a more aggressive behavior will transform the clinical management of this disease. If both patients and clinicians would have reproducible and valid tools to estimate the specific risk of morbidity associated with PCa, then many patients would opt to and join active surveillance (AS) protocols, and consequently costs and comorbidities associated with the current overtreatment of prostate cancer would be reduced. Thus, a biomarker, or a panel of biomarkers, with high specificity to identify patients at risk for progression in AS protocols, would identify those men who could benefit from less intensive AS protocols with less repeated biopsies, so reducing the risk and cost of these invasive procedures. In this review we try to offer an overview of the new markers identified by genomic techniques and to discuss their potential role in an AS context. Moreover, the AS protocol offers an adequate setting for validation of biomarkers associated to disease progression.
在前列腺癌（PCa）诊断时，识别与疾病存在或更具侵袭性的行为相关的生物标志物，将改变这种疾病的临床管理。如果患者和临床医生都能拥有可重复且有效的工具来评估与PCa相关的特定发病风险，那么许多患者会选择并参与主动监测（AS）方案，从而降低与当前前列腺癌过度治疗相关的成本和合并症。因此，一种对识别AS方案中进展风险患者具有高特异性的生物标志物或一组生物标志物，将识别出那些可以从强度较低、活检次数较少的AS方案中获益的男性，从而降低这些侵入性检查的风险和成本。在本综述中，我们试图概述通过基因组技术鉴定的新标志物，并讨论它们在AS背景下的潜在作用。此外，AS方案为验证与疾病进展相关的生物标志物提供了一个合适的环境。
